Fc‐Fusion proteins represent a successful class of biopharmaceutical products, with already
13 drugs approved in the European Union and United States as well as three biosimilar …

Peptides and proteins are preponderantly emerging in the drug market, as shown by the
increasing number of biopharmaceutics already approved or under development …

Streptococcal pyrogenic exotoxin B (SpeB) is a cysteine protease expressed during group A
streptococcal infection that represents a major virulence factor. Although subject to several …

UV and ambient light-induced modifications and related degradation of therapeutic proteins
are observed during manufacturing and storage. Therefore, to ensure product quality …

Monoclonal antibodies (mAbs) are amazingly successful in treating diseases such as
various types of cancers, immune disorders, and infections. Currently, mAbs are considered …

The growing complexity of novel biopharmaceutical formats, such as Fc-fusion proteins, in
increasingly competitive environment has highlighted the need of high-throughput analytical …

Etanercept is a recombinant Fc fusion protein widely used to treat rheumatic diseases. This
protein is highly glycosylated and contains numerous O-and N-glycosylation sites. Since …

The conserved region (Fc) of IgG antibodies dictates the interactions with designated
receptors thus defining the immunological effector functions of IgG. Amino acid sequence …

Antibody–drug conjugates (ADCs) represent an important class of new biopharmaceutical
modalities. ADCs are highly complex and heterogeneous molecules, potentially containing …

Therapeutic proteins are an indispensable class of drugs and often therapeutics of last
resort. They are sensitive to oxidation, which is of critical concern, because it can affect drug …